Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Dinitrophenylene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA5A | P35218 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dinitrophenylene SCHEMBL11883873 | 0.96 | TSHR (0.71) | TSHRLMNAKMT2AHTTGAA | |
| Sulfuric Acid SCHEMBL34068 | 0.92 | TSHR (0.65) | TSHRLMNAKMT2AHTTGAA | |
| Dinitrophenylene SCHEMBL28595103 | 0.91 | TSHR (0.71) | TSHRLMNAKMT2AHTTGAA | |
| Dinitrophenylene SCHEMBL9798067 | 0.91 | TSHR (0.71) | TSHRLMNAKMT2AHTTGAA | |
| Dinitrophenylene SCHEMBL29291896 | 0.88 | TSHR (1.00) | TSHRLMNAKMT2AHTTGAA | |
| Dinitrophenylene SCHEMBL36632 | 0.88 | TSHR (1.00) | TSHRLMNAKMT2AHTTGAA | |
| Dinitrophenylene SCHEMBL27494392 | 0.88 | TSHR (0.65) | TSHRLMNAKMT2AHTTGAA | |
| Sulfuric Acid SCHEMBL30827375 | 0.88 | TSHR (0.59) | TSHRLMNAKMT2AHTTGAA | |
| 3-Nitro-Phenol SCHEMBL28727747 | 0.88 | TSHR (0.85) | TSHRLMNAKMT2AHTTGAA | |
| Dinitrophenylene SCHEMBL8975758 | 0.86 | TSHR (0.77) | TSHRLMNAKMT2AHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025469-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20240325398-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11944631-B2 | Combination therapies | INFINITY PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20220125794-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11110096-B2 | Combination therapies | INFINITY PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2021-03-25 | — | — | US | disclosed |
| US-20200338083-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2020-10-29 | — | — | US | disclosed |
| CN-105622756-B | L OX and L OX L2 inhibitors and application thereof | 吉利德生物制剂公司 | 2020-07-28 | — | — | CN | disclosed |
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2019-01-24 | — | — | US | disclosed |
| US-20180371551-A1 | MAT2A INHIBITORS FOR TREATING MTAP NULL CANCER | SERVIER PHARMACEUTICALS LLC | 2018-12-27 | — | — | US | disclosed |
| EP-0494135-A1 | DETECTION AND QUANTIFICATION OF -i(NEU) RELATED PROTEINS IN THE BIOLOGICAL FLUIDS OF HUMANS. | ONCOGENETICS PARTNERS (US) | 1992-07-15 | — | — | EP | disclosed |
| EP-0471825-A1 | PTPase DIAGNOSTICS AND USES THEREOF | APPLIED BIOTECHNOLOGY, INC. (US) | 1992-02-26 | — | — | EP | disclosed |
| WO-1991017764-A1 | IMMUNOGENIC PEPTIDES, ANTIBODIES AND USES THEREOF RELATING TO CD4 RECEPTOR BINDING | DANA FARBER CANCER INSTITUTE (US) | 1991-11-28 | — | — | WO | disclosed |
| EP-0453560-A1 | LOCALIZATION AND CHARACTERIZATION OF THE WILMS'S TUMOR GENE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-10-30 | — | — | EP | disclosed |
| WO-1991013173-A1 | PTPase DIAGNOSTICS AND USES THEREOF | APPLIED BIOTECHNOLOGY, INCORPORATED (US) | 1991-09-05 | — | — | WO | disclosed |
| EP-0411018-A4 | DETECTION, QUANTITATION AND CLASSIFICATION OF RAS PROTEINS IN BODY FLUIDS AND TISSUES | — | 1991-08-21 | — | — | EP | disclosed |
| WO-1991007509-A1 | LOCALIZATION AND CHARACTERIZATION OF THE WILMS'S TUMOR GENE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-05-30 | — | — | WO | disclosed |
| WO-1991005264-A1 | DETECTION AND QUANTIFICATION OF NEU RELATED PROTEINS IN THE BIOLOGICAL FLUIDS OF HUMANS | ONCOGENETICS PARTNERS (US) | 1991-04-18 | — | — | WO | disclosed |
| EP-0411018-A1 | DETECTION, QUANTITATION AND CLASSIFICATION OF RAS PROTEINS IN BODY FLUIDS AND TISSUES. | DU PONT (US) | 1991-02-06 | — | — | EP | disclosed |
| WO-1989010565-A1 | DETECTION, QUANTITATION AND CLASSIFICATION OF RAS PROTEINS IN BODY FLUIDS AND TISSUES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025469-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL3 | TSHR 4453/4885LMNA 2557/4885KMT2A 2618/4885 |
| US-20200338083-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | TSHR 2771/4885LMNA 2976/4885KMT2A 343/4885 |
| US-20220125794-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL3 | TSHR 4453/4885LMNA 2557/4885KMT2A 2618/4885 |
| US-11944631-B2 | Combination therapies | BCL2, BAK1, BCL3 | TSHR 4453/4885LMNA 2557/4885KMT2A 2618/4885 |
| US-20180371551-A1 | MAT2A INHIBITORS FOR TREATING MTAP NULL CANCER | MAT2A, MNAT1, MAT2B | TSHR 3173/4885LMNA 2607/4885KMT2A 26/4885 |
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | TSHR 4042/4885LMNA 4346/4885KMT2A 1847/4885 |
| US-20240325398-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | TSHR 2771/4885LMNA 2976/4885KMT2A 343/4885 |
| US-11110096-B2 | Combination therapies | BCL2, BAK1, BCL3 | TSHR 4453/4885LMNA 2557/4885KMT2A 2618/4885 |
| US-20210088520-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | TSHR 4042/4885LMNA 4346/4885KMT2A 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.